ACP Journal Club. Aliskiren increased adverse events in patients with diabetes and kidney disease who were receiving ACE inhibitors or ARBs.

@article{Leeuw2013ACPJC,
  title={ACP Journal Club. Aliskiren increased adverse events in patients with diabetes and kidney disease who were receiving ACE inhibitors or ARBs.},
  author={Peter W de Leeuw},
  journal={Annals of internal medicine},
  year={2013},
  volume={158 6},
  pages={
          JC7
        }
}
Patients: 8606 adults ≥ 35 years of age (mean age 64 y, 68% men, 98% with chronic kidney disease) who had type 2 diabetes and albuminuria, or CV disease with reduced estimated glomerular filtration rate (30 to < 60 mL/min/1.73 m2), and were treated with angiotensin-converting enzyme (ACE) inhibitors or angiotensinreceptor blockers (ARBs). Exclusion criteria included serum potassium > 5.0 mmol/L or unstable renal or CV status. 
Tweets
This paper has been referenced on Twitter 1 time. VIEW TWEETS